Anbio Biotechnology Registered (A) Aktie
Marktkapitalisierung
45,44 Mio. $
45,44 Mio. $
Streubesitz
90,32%
KGV
187,94
Index-Zuordnung
-
Anbio Biotechnology Class A Ordinary Shares Unternehmensprofil
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.
Vorstand
Herr Michael Lau M.B.A., Ph.D.
Geschäftsführender Direktor
Frau Suki Song CPA
Finanzvorstand
Herr Chris Tian
Geschäftsführender Direktor
Aktionärsstruktur
90,431%
Freefloat
85,532%
Individuelle Aktionäre
4,899%
Institutionelle Aktionäre
Termine
Stammdaten
| Nennwert/Aktie | - |
| Land | USA |
| Währung | USD |
| Branche | Medizinische Instrumente & Zubehör |
| Aktientyp | - |
| Sektor | Gesundheit |
| Gattung | - |
Quelle: Leeway